Skip to main content

Table 3 Clinical outcomes and complications

From: Evaluation of GnRH antagonist pretreatment before ovarian stimulation in a GnRH antagonist protocol in normal ovulatory women undergoing IVF/ICSI: a randomized controlled trial

Variable

study group

control group

p- value

No.of ET cycle (n)

59

58

ET cycle cancellation rates (n, %)

9/68(13.2)

10/68(14.7)

0.805

No.of Embryos transfered (n), mean ± SD

1.9 ± 0.3

1.9 ± 0.4

0.550

Implantation rate n,(%)

37/112(33.0)

39/108(36.1)

0.632

Pregnancy

 Biochemical pregnancy rate per ET cycle n,(%)

36/59(61.0)

35/58(60.3)

0.941

 Clinical pregnancy rate per ET cycle, n, (%)

27/59(45.8)

31/58(53.4)

0.406

 Ongoing pregnancy rate per ET cycle, n,(%)

20/59(33.9)

26/58(45.6)

0.306

 Live-birth rate per ET cycle, n,(%)

20/59(33.9)

25/58(43.1)

0.197

Pregnancy loss

 Biochemical pregnancy, n,(%)

9/36(25.0)

4/35(11.4)

0.139

 Abortion rate, n,(%)

5/27(18.5)

4/31(12.9)

0.556

 Ectopic pregnancy rate, n,(%)

2/27(7.4)

2/31(6.5)

0.886

Complication

 Incidence of moderate-to-severe OHSS, n,(%)

1/68(1.5)

2/68(2.9)

0.559

  1. Note: ET embryo  transfer, SD standard deviation